Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504911 | 0.93 | KDM4E (0.46) | KDM4EGRIN2BANPEPERAP2 | |
| SCHEMBL5504924 | 0.91 | KDM4E (0.48) | KDM4EANPEPERAP2 | |
| SCHEMBL6009887 | 0.91 | KDM4E (0.48) | KDM4EANPEPERAP2 | |
| SCHEMBL5504116 | 0.76 | ANPEP (0.33) | ANPEPERAP2 | |
| SCHEMBL6009426 | 0.75 | GRIN2B (0.53) | KDM4EGRIN2B | |
| SCHEMBL5503709 | 0.74 | EPHX2 (0.36) | — | |
| SCHEMBL5504983 | 0.73 | ADH1B (0.36) | ANPEPERAP2 | |
| SCHEMBL6009038 | 0.72 | ADH1B (0.39) | — | |
| SCHEMBL5500654 | 0.69 | KDM4E (0.35) | KDM4EGRIN2BANPEPERAP2 | |
| SCHEMBL5510014 | 0.69 | MAOA (0.47) | KDM4EGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | KDM4E 4725/4885GRIN2B 2271/4885ANPEP 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.